Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects

Cytokines, Cellular and Molecular Therapy

Volumn 5, Issue 4, 1999, Pages 217-225

  Bowne, Wilbur B ^a   Wolchok, Jedd D ^a   Hawkins, William G ^a   Srinivasan, Roopa ^a   Gregor, Polly ^a   Blachere, Nathalie E ^a   Moroi, Yoichi ^a   Engelhorn, Manuel E ^a   Houghton, Alan N ^a   Lewis, Jonathan J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant; DNA; GM CSF; Vaccine

Indexed keywords

DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLASMID DNA; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE TRANSFER; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; BIOLISTICS; BLOTTING, WESTERN; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMIS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INJECTIONS, INTRADERMAL; LYMPH NODES; MELANOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PRECIPITIN TESTS; T-LYMPHOCYTES; VACCINES, DNA;

EID: 0033499108     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Houghton AN, Cancer antigens: immune recognition of self and altered self. J Exp Med (1994) 180: 1-4.
2. Lewis JJ, Houghton AN, Definition of tumor antigens suitable for vaccine construction. Semin Cancer Biol (1995) 6: 321-7.
3. Dyall R, Vasovic LV, Molano A et al, CD4-independent in vivo priming of murine CTL by optimal MHC class I-restricted peptides derived from intracellular pathogens. Int Immunol (1995) 7: 1205-12.
4. Kim JJ, Simbiri KA, Sin JI et al, Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J Interferon Cytokine Res (1999) 19: 77-84.
5. Sin JI, Kim JJ, Ugen KE et al, Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes. Eur J Immunol (1998) 28: 3530-40.
6. Hara I, Takechi Y, Houghton AN, Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med (1995) 182: 1609-14.
7. Ross HM, Weber LW, Wang S et al, Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. Clin Cancer Res (1997) 3: 2191-6.
8. Weber LW, Bowne WB, Wolchok JD et al, Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest (1998) 102: 1258-64.
9. Mackenzie IC, Squier CA, Cytochemical identification of ATPase-positive Langerhans cells in EDTA-separated sheets of mouse epidermis. Br J Dermatol (1975) 92: 523-33.
10. Wolff K, Winkelmann RK, Quantitative studies on the Langerhans cell population of guinea pig epidermis. J Invest Dermatol (1967) 48: 504-13.
11. Wolff K, Winkelmann RK, Ultrastructural localization of nucleoside triphosphatase in Langerhans cells. J Invest Dermatol (1967) 48: 50-4.
12. Porgador A, Irvine KR, Iwasaki A et al, Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med (1998) 188: 1075-82.
13. Noguchi Y, Chen YT, Old LJ, A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA (1994) 91: 3171-5.
14. Inaba K, Inaba M, Romani N et al, Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med (1992) 176: 1693-702.
15. Heufler C, Koch F, Schuler G, Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med (1988) 167: 700-5.
16. Schuler G, Steinman RM, Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med (1985) 161: 526-46.
17. Witmer-Pack MD, Olivier W, Valinsky J et al, Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J Exp Med (1987) 166: 1484-98.
18. Kaplan G, Walsh G, Guido LS et al, Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med (1992) 175: 1717-28.
19. Disis ML, Bernhard H, Shiota FM et al, Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood (1996) 88: 202-10.
20. Nigam A, Yacavone RF, Zahurak ML et al, Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int J Oncol (1998) 12: 161-70.
21. Mahvi DM, Sondel PM, Yang NS et al. Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma. Hum Gene Ther (1997) 8: 875-91.
22. Aruga E, Aruga A, Area MJ et al, Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF. Cancer Gene Ther (1997) 4: 157-66.
23. Nagai E, Ogawa T, Kielian T et al, Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate preexisting tumors in syngeneic mice. Cancer Immunol Immunother (1998) 47: 72-80.
24. Jaffee EM, Abrams R, Cameron J et al, A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum Gene Ther (1998) 9: 1951-71.
25. Dranoff G, Jaffee E, Lazenby A et al, Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA (1993) 90: 3539-43.
26. Bueler H, Mulligan RC, Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1. Mol Med (1996) 2: 545-55.
27. McLaughlin JP, Abrams S, Kantor J et al, Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity. J Immunother (1997) 20: 449-59.
28. Simons JW, Jaffee EM, Weber CE et al, Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res (1997) 57: 1537-46.
29. Thomas MC, Greten TF, Pardoll DM et al. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther (1998) 9: 835-43.
30. Pardoll DM, Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol (1995) 13: 399-415.
31. Golumbek PT, Azhari R, Jaffee EM et al, Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res (1993) 53: 5841-4.
32. Tanigawa K, Yu H, Sun R et al, Gene gun application in the generation of effector T cells for adoptive immunotherapy. Cancer Immunol Immunother (2000) 48: 635-643.
33. Bowne WB, Srinivasan R, Wolchok JD et al, Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med (1999) 190: 1717-22.